N
Description
Nanexa AB is a Swedish pharmaceutical development company based in Uppsala, founded in 2007, specializing in injectable products based on its proprietary PharmaShell® technology. This platform uses atomic layer deposition (ALD) to coat drug particles with nanometric precision, enabling high drug load long-acting injectables. Listed on Nasdaq Stockholm. Has signed agreements with AstraZeneca, Novo Nordisk and Moderna (license/option agreement worth up to $500M in milestones).